1. Home
  2. PT vs MBRX Comparison

PT vs MBRX Comparison

Compare PT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PT
  • MBRX
  • Stock Information
  • Founded
  • PT 2012
  • MBRX 2015
  • Country
  • PT China
  • MBRX United States
  • Employees
  • PT N/A
  • MBRX N/A
  • Industry
  • PT Computer Software: Programming Data Processing
  • MBRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PT Technology
  • MBRX Health Care
  • Exchange
  • PT Nasdaq
  • MBRX Nasdaq
  • Market Cap
  • PT 15.2M
  • MBRX 12.9M
  • IPO Year
  • PT 2018
  • MBRX 2016
  • Fundamental
  • Price
  • PT $0.90
  • MBRX $0.31
  • Analyst Decision
  • PT
  • MBRX Strong Buy
  • Analyst Count
  • PT 0
  • MBRX 3
  • Target Price
  • PT N/A
  • MBRX $5.33
  • AVG Volume (30 Days)
  • PT 15.7K
  • MBRX 5.2M
  • Earning Date
  • PT 07-07-2025
  • MBRX 08-13-2025
  • Dividend Yield
  • PT N/A
  • MBRX N/A
  • EPS Growth
  • PT N/A
  • MBRX N/A
  • EPS
  • PT N/A
  • MBRX N/A
  • Revenue
  • PT $4,814,566.00
  • MBRX N/A
  • Revenue This Year
  • PT N/A
  • MBRX N/A
  • Revenue Next Year
  • PT N/A
  • MBRX N/A
  • P/E Ratio
  • PT N/A
  • MBRX N/A
  • Revenue Growth
  • PT N/A
  • MBRX N/A
  • 52 Week Low
  • PT $0.76
  • MBRX $0.25
  • 52 Week High
  • PT $1.15
  • MBRX $4.71
  • Technical
  • Relative Strength Index (RSI)
  • PT 46.18
  • MBRX 24.39
  • Support Level
  • PT $0.82
  • MBRX $0.25
  • Resistance Level
  • PT $0.94
  • MBRX $0.42
  • Average True Range (ATR)
  • PT 0.06
  • MBRX 0.06
  • MACD
  • PT 0.00
  • MBRX -0.03
  • Stochastic Oscillator
  • PT 57.14
  • MBRX 13.07

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Share on Social Networks: